{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:29:04Z","timestamp":1787678944547,"version":"build-2784847793"},"reference-count":27,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This article summarizes a presentation titled \u2018The role of topical therapies along the psoriasis patient journey\u2019 held at the Satellite Symposium of the 30<jats:sup>th<\/jats:sup> European Academy of Dermatology and Venereology Congress. During this session, the role of topical treatments in the management of psoriasis was presented, with a particular focus on the current unmet needs and data gaps. Psoriasis plays a significant role in a patient's daily life, impacting them not only physically but also psychologically and socially. The disease burden increases with duration and severity. Topical therapies are the keystone of the management of psoriasis. About 70%\u201380% of patients present a mild\u2010to\u2010moderate form of psoriasis that can be successfully treated with topical agents. According to a German recommendation, patients with mild psoriasis should initiate a topical therapy in combination with skin care products. In the real\u2010life setting, the calcipotriol\/betamethasone dipropionate (CAL\/BDP) fixed combination was the most prescribed topical treatment for beyond\u2010mild patients in Germany, Spain and the United Kingdom. Healthcare professionals also often or very often prescribed topicals as an alternative to non\u2010biologic systemics in certain situations, such as patient preference (51%), contraindication (50%) and to limit side effects (26%). Adjunctive topical therapy to patients using systemic therapy is used to optimize treatment outcomes and improving the quality of life for patients. Topical treatments can be also effective in severe forms of psoriasis. However, there are still some gaps and unmet needs on topical therapy. Ineffectiveness, patient dissatisfaction and adherence are the largest barriers to treatment success. Main strengths of topical treatments include the availability of various topical ingredients and galenics, the adaptability to different anatomical areas and the possible combination with phototherapy and systemics. Moreover, patients in specific situations can benefit from switching to topical treatments (e.g. pregnancy or surgery).<\/jats:p>","DOI":"10.1111\/jdv.18761","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T10:48:03Z","timestamp":1671706083000},"page":"3-8","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The role of topical therapies along the psoriasis patient journey: An overview from the Symposium \u2018<i>Tailoring topical psoriasis treatments to patients' needs and expectations<\/i>\u2019 of the 30<sup>th<\/sup><scp>EADV<\/scp> Congress 2021"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Hospital Frankfurt am Main  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Peter","family":"van de Kerkhof","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00635-4"},{"key":"e_1_2_13_4_1","unstructured":"World Health Organization.Global report on psoriasis. 2016 [last accessed 2022 Apr 12]. Available from:https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf.psoriasis?sequence=1"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07405.x"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000512930"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13150"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/ddg.14507","article-title":"German S3\u2010guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm \u2010 part 2: treatment monitoring and specific clinical or comorbid situations","volume":"19","author":"Nast A","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17053"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13810"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00501-3"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09791.x"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000084753"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1729335"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2012.12.005"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1675855"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101108"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.711756"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1544413"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.101964"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17734"},{"key":"e_1_2_13_24_1","first-page":"242","article-title":"Pooled analysis demonstrating superior patient\u2010 reported psoriasis treatment outcomes for calcipotriene\/betamethasone dipropionate cream versus suspension\/gel","volume":"21","author":"Armstrong A","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_25_1","first-page":"122","article-title":"Tapinarof cream (Vtama) for psoriasis","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629"},{"key":"e_1_2_13_27_1","unstructured":"ZORYVE\u2122 (roflumilast) cream for topical use. Full prescribing information. 2022 [last accessed 2022 Aug 29]. Available from:https:\/\/www.arcutis.com\/wp\u2010content\/uploads\/USPI\u2010roflumilast\u2010cream\u2010FDAapproved\u2010V1\u201029Jul2022.pdf"},{"issue":"1","key":"e_1_2_13_28_1","first-page":"78S","article-title":"Roflumilast cream, a once\u2010daily, potent phosphodiesterase\u20104 inhibitor, in chronic plaque psoriasis patients: efficacy and safety from DERMIS\u20101 and DERMIS\u20102 phase 3 trials","volume":"25","author":"Lebwohl MG","year":"2021","journal-title":"J Cutan Med Surg"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18761","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18761","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T07:39:33Z","timestamp":1692517173000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":27,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/jdv.18761"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18761","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"2022-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}